DDInter1562 DDInter535
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255647,L44612]
Raloxifene {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) upregulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) causes {v} (Side Effect) Flushing
Flushing {u} (Side Effect) is caused by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is regulated by {v} (Gene) CEBPD
CEBPD {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is regulated by {v} (Gene) CA2
CA2 {u} (Gene) is bound by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) downregulates {v} (Gene) NOSIP
NOSIP {u} (Gene) regulates {v} (Gene) KRT19
KRT19 {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) downregulates {v} (Gene) NUP93
NUP93 {u} (Gene) is regulated by {v} (Gene) LAP3
LAP3 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) upregulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is regulated by {v} (Gene) KDM5A
KDM5A {u} (Gene) is upregulated by {v} (Compound) Diazoxide
Raloxifene {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Raloxifene {u} (Compound) downregulates {v} (Gene) NUP93
NUP93 {u} (Gene) regulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Raloxifene (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Diazoxide (Compound)
Raloxifene (Compound) upregulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Diazoxide (Compound)
Raloxifene (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Diazoxide (Compound)
Raloxifene (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is regulated by CEBPD (Gene) and CEBPD (Gene) is upregulated by Diazoxide (Compound)
Raloxifene (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is regulated by CA2 (Gene) and CA2 (Gene) is bound by Diazoxide (Compound)
Raloxifene (Compound) downregulates NOSIP (Gene) and NOSIP (Gene) regulates KRT19 (Gene) and KRT19 (Gene) is upregulated by Diazoxide (Compound)
Raloxifene (Compound) downregulates NUP93 (Gene) and NUP93 (Gene) is regulated by LAP3 (Gene) and LAP3 (Gene) is downregulated by Diazoxide (Compound)
Raloxifene (Compound) upregulates ACOT9 (Gene) and ACOT9 (Gene) is regulated by KDM5A (Gene) and KDM5A (Gene) is upregulated by Diazoxide (Compound)
Raloxifene (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Raloxifene (Compound) downregulates NUP93 (Gene) and NUP93 (Gene) regulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Diazoxide (Compound)